rss
J Clin Pathol 2007;60:709-714 doi:10.1136/jcp.2006.039917
  • Original article

Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis

  1. Paulette Mhawech-Fauceglia1,
  2. Rhakee Saxena2,
  3. Shaozeng Zhang1,
  4. Luigi Terracciano3,
  5. Guido Sauter4,
  6. Arundhuti Chadhuri1,
  7. Francois R Herrmann5,
  8. Remedios Penetrante1
  1. 1Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
  2. 2Department of Pathology, Buffalo General Hospital, Buffalo, New York, USA
  3. 3Institute of Pathology, Basel University Hospital, Basel, Switzerland
  4. 4Department of Pathology, University Medical Center Hamburg, Eppendorf, Hamburg, Germany
  5. 5Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland
  1. Correspondence to:
 Professor P Mhawech-Fauceglia
 Department of Pathology, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA; pmhawech1{at}yahoo.com
  • Accepted 7 July 2006
  • Published Online First 12 July 2006

Abstract

Background: Pax-5 belongs to the Pax gene family transcription factors that play an important role in organogenesis and in B cell ontogeny. It is expressed in B cell non-Hodgkin’s lymphoma (B-NHL), Hodgkin’s lymphoma (HL) and neuroendocrine carcinomas. However, its expression in other tumour types is not fully explored.

Aims and methods: To determine Pax-5 expression in other tumour types, immunohistochemistry was performed on 3758 benign and malignant tumours using multiple tumour microarrays, as well as on whole sections.

Results: Pax-5 was expressed in 108/118 (91.5%) B-NHLs, in 60/70 (85.7%) HLs and in 0/7 T cell lymphomas. In addition, Pax-5 was seen in 24/34 (70.6%) Merkel cell carcinomas, 42/53 (79.2%) small cell carcinomas, 1/164 (0.6%) breast carcinomas, 2/204 (1%) endometrial adenocarcinomas and 1/452 (0.2%) urothelial carcinoma of the bladder.

Conclusion: Despite its expression in a small subset of malignancies of epithelial origin, Pax-5 is still a good and reliable immunomarker in diagnosing B-NHL, HL and neuroendocrine carcinomas.

Footnotes

  • Published Online First 12 July 2006

  • Competing interests: None declared.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. jcp.2006.039917v1
    2. 60/6/709 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Latest from JCP Education

Latest from JCP Education

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
View free sample issue >>

Free archive
The full back archive is now available for JCP. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    • Latest Pathology jobs

    Latest Pathology jobs

    Show me all Pathology
    jobs >>